H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Indaptus Therapeutics (INDP – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $1.95.
Selvaraju covers the Healthcare sector, focusing on stocks such as Inovio Pharmaceuticals, Axsome Therapeutics, and MoonLake Immunotherapeutics. According to TipRanks, Selvaraju has an average return of -14.6% and a 30.80% success rate on recommended stocks.
Currently, the analyst consensus on Indaptus Therapeutics is a Moderate Buy with an average price target of $8.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $3.40 and a one-year low of $1.25. Currently, Indaptus Therapeutics has an average volume of 28.75K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company engaging in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.
Read More on INDP:
- Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
- Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform
- Indaptus Therapeutics’ Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit
- Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023
- UPDATE — Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023
